Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer

Exclusion Criteria

• •1. Patients with platelets \<70×109/L, severe bleeding tendency and coagulation dysfunction that cannot be corrected in a short term.
• •2. Patients with severe pulmonary fibrosis and pulmonary arterial hypertension.
• •3. Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever \>38.5°C.
• •4. Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in a short term.
• •5. Those with poorly controlled malignant pleural effusions.
• •6. Anticoagulation therapy and/or anti-platelet drugs (except dabigatran, rivaroxaban and other new oral anticoagulants) have not been discontinued more than 5\~7d before ablation.
• •7. Eastern Cooperative Oncology Group (ECOG) score \>2.
• •8. Combination with other tumors with extensive metastases and an expected survival of \<6 months.
• •9. Patients with episodic psychosis.
• •10. Pregnant women, or patients with pregnancy plan during the study period.
• •11. Have participated or are participating in other clinical studies within 30 days.
• •12. Any other condition that the investigator considers inappropriate for participation in this study.